Complete baseline data were available for 67 888 patients at time of baseline publication. Complete 1-year follow-up data were available for 64 977 patients (lost to follow-up were 3248 patients who did not attend 1-year visit and 11 who withdrew consent). At the 3-year follow-up, 48 050 patients were eligible. Complete 3-year follow-up data were available for 36 608 patients (2301 died before the 2-year follow-up; lost to follow-up were 8712 who did not attend 3-year visit and 429 who withdrew consent).
Only first events are included. CV indicates cardiovascular; MI, myocardial infarction.
Ischemic events were defined as myocardial infarction (MI) or stroke. Diabetes status was missing for 3 patients: 2 patients in the category risk factors only and 1 patient in the category stable atherosclerosis without prior ischemic events. Error bars indicate 95% confidence intervals for each event rate; CV indicates cardiovascular.
Ischemic events were defined as myocardial infarction (MI) or stroke. Error bars indicate 95% confidence intervals for each event rate; CV indicates cardiovascular.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Bhatt DL, Eagle KA, Ohman EM, et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA. 2010;304(12):1350–1357. doi:10.1001/jama.2010.1322
Context Clinicians and trialists have difficulty with identifying which patients are highest risk for cardiovascular events. Prior ischemic events, polyvascular disease, and diabetes mellitus have all been identified as predictors of ischemic events, but their comparative contributions to future risk remain unclear.
Objective To categorize the risk of cardiovascular events in stable outpatients with various initial manifestations of atherothrombosis using simple clinical descriptors.
Design, Setting, and Patients Outpatients with coronary artery disease, cerebrovascular disease, or peripheral arterial disease or with multiple risk factors for atherothrombosis were enrolled in the global Reduction of Atherothrombosis for Continued Health (REACH) Registry and were followed up for as long as 4 years. Patients from 3647 centers in 29 countries were enrolled between 2003 and 2004 and followed up until 2008. Final database lock was in April 2009.
Main Outcome Measures Rates of cardiovascular death, myocardial infarction, and stroke.
Results A total of 45 227 patients with baseline data were included in this 4-year analysis. During the follow-up period, a total of 5481 patients experienced at least 1 event, including 2315 with cardiovascular death, 1228 with myocardial infarction, 1898 with stroke, and 40 with both a myocardial infarction and stroke on the same day. Among patients with atherothrombosis, those with a prior history of ischemic events at baseline (n = 21 890) had the highest rate of subsequent ischemic events (18.3%; 95% confidence interval [CI], 17.4%-19.1%); patients with stable coronary, cerebrovascular, or peripheral artery disease (n = 15 264) had a lower risk (12.2%; 95% CI, 11.4%-12.9%); and patients without established atherothrombosis but with risk factors only (n = 8073) had the lowest risk (9.1%; 95% CI, 8.3%-9.9%) (P < .001 for all comparisons). In addition, in multivariable modeling, the presence of diabetes (hazard ratio [HR], 1.44; 95% CI, 1.36-1.53; P < .001), an ischemic event in the previous year (HR, 1.71; 95% CI, 1.57-1.85; P < .001), and polyvascular disease (HR, 1.99; 95% CI, 1.78-2.24; P < .001) each were associated with a significantly higher risk of the primary end point.
Conclusion Clinical descriptors can assist clinicians in identifying high-risk patients within the broad range of risk for outpatients with atherothrombosis.
Patients with atherothrombosis are at elevated risk of ischemic events but, depending on their specific manifestations of atherothrombosis, may have varying degrees of future risk for ischemic events. Accurate knowledge of the major determinants of subsequent ischemic risk would be extremely useful, both for clinical and investigational purposes.
Several recent clinical trials of new agents in acute coronary syndromes, stable atherosclerosis, and diabetes mellitus have reported event rates lower than initially projected.1-6 The ability to identify patients at highest risk of cardiovascular events would allow trials of novel therapies to focus on those patients most likely to derive benefit. For clinicians, the ability to identify rapidly the major determinants of risk among patients with atherosclerosis would be useful to triage novel preventive therapies toward those at the higher end of the risk spectrum. Thus, the international Reduction of Atherothrombosis for Continued Health (REACH) Registry, a contemporary data set comprising patients with various manifestations of atherosclerosis, spanning from asymptomatic adults with risk factors, to patients with stable atherosclerosis, to those with prior ischemic events, would be potentially useful to establish the risk of future ischemic events. Herein, the 4-year results of the REACH Registry are presented.
The methods of the REACH Registry have been published in detail previously.7-10 This protocol was submitted to institutional review boards in each country according to the local requirements and signed informed consent was required for all patients. Briefly, patients at least 45 years old with 3 or more risk factors for atherosclerosis and patients with established coronary artery disease, peripheral arterial disease, or cerebrovascular disease were enrolled. The multiple risk factors category consisted of diabetes, diabetic nephropathy, ankle-brachial index less than 0.9, asymptomatic carotid stenosis of 70% or more, carotid intima media thickness at least 2 times that at adjacent sites, systolic blood pressure of 150 mm Hg or higher despite treatment, hypercholesterolemia treated with medication, current smoking of 15 or more cigarettes per day, and age 65 years and older for men or 70 years and older for women.
Documented coronary artery disease consisted of 1 or more of the following: stable angina, history of unstable angina, history of percutaneous coronary intervention, history of coronary artery bypass grafting, or previous myocardial infarction. Documented cerebrovascular disease consisted of a neurologist report or hospital report with the diagnosis of ischemic stroke or transient ischemic attack. Documented peripheral artery disease consisted of current intermittent claudication with ankle-brachial index of less than 0.9 and/or a history of intermittent claudication together with a previous intervention, such as angioplasty, stenting, atherectomy, peripheral arterial bypass grafting, or other vascular interventions, including amputations. Diabetes was defined as any history of diabetes or current diabetes (diagnosed by at least 2 fasting blood glucose measures >126 mg/dL; to convert to mmol/L, multiply by 0.0555) treated with medication, lifestyle, or both.
Detailed information was collected at baseline, with subsequent annual follow-up at 1, 2, 3, and 4 years.7,9 Patients were enrolled between 2003 and 2004 and followed up until 2008. Final database lock was in April 2009. The initial follow-up was planned for up to 2 years and shortly before that point, an additional 2-year extension was proposed. Not all countries and sites that were in the 2-year follow-up cohort elected to continue participation in the registry, largely for financial reasons, although the majority did elect to continue. Countries and sites that decided not to participate in the 4-year follow-up were excluded from the results.
Event rates of cardiovascular death, myocardial infarction, stroke, and cardiovascular hospitalization were calculated. End points were not adjudicated. Cardiovascular death included fatal stroke, fatal myocardial infarction, or other cardiovascular death. Other cardiovascular death included other death of cardiac origin; pulmonary embolism; any sudden death including unobserved and unexpected death (eg, death while sleeping) unless proven otherwise by autopsy; death following a vascular operation, vascular procedure, or amputation; death attributed to heart failure; death following a visceral or limb infarction; and any other death that could not be definitely attributed to a nonvascular cause or hemorrhage. Any myocardial infarction or stroke followed by a death whatever the cause in the next 28 days was considered to be a fatal myocardial infarction or fatal stroke. Cardiovascular hospitalization consisted of hospitalization for unstable angina, transient ischemic attack, worsening of claudication related to peripheral artery disease, other ischemic arterial event, coronary artery bypass grafting, coronary angioplasty/stenting, carotid surgery, carotid angioplasty/stenting, amputation affecting lower limbs, peripheral bypass graft, or angioplasty/stenting for peripheral artery disease.
Groups based on the enrollment criteria of risk factors only (for example, diabetic patients without established disease), stable atherosclerosis (without prior myocardial infarction or stroke but with atherosclerosis established objectively, for example, patients with a history of revascularization), or prior ischemic events (myocardial infarction or stroke) were compared. On the case report form, the time of previous ischemic event was recorded as 1 year or less or longer than 1 year; no specific date of event was recorded. For the purposes of comparing event rates, patients were also classified as having diabetes or polyvascular disease at baseline. Polyvascular disease was defined as having atherothrombosis in 2 or 3 arterial beds (coronary, peripheral, cerebrovascular) at baseline.
All analyses were performed on patients eligible for the 4-year follow-up study, defined as all patients who completed at least 1 postbaseline follow-up visit and who were enrolled at centers that agreed to participate in the 4-year follow-up study. Continuous variables are expressed as mean (standard deviation), and categorical variables are expressed as frequencies and percentages. Cumulative incidence rates are reported after adjustment for age and sex. Multivariable analysis was performed to determine the predictors of 4-year cardiovascular death, myocardial infarction, or stroke; the variables entered in the Cox model were sex; age; current smoker; history of diabetes; body mass index less than 20 (calculated as weight in kilograms divided by height in meters squared); ischemic event (≤1 year, >1 year, or no ischemic event); vascular disease status (polyvascular disease, single vascular disease, or risk factors only); congestive heart failure; atrial fibrillation/flutter; statins (at baseline); aspirin (at baseline); and Eastern Europe, Middle East, or Japan vs other regions. Geographic regions were collapsed into higher (Eastern Europe and Middle East) and lower (Japan) risk locations.
Candidate variables considered in that model that were not significant included systolic and diastolic blood pressure at baseline, cholesterol levels at baseline, and blood pressure treatment. No method was used to impute missing values or adjust the model for the presence of missing data, as the frequency of baseline missing data was very low (under 1% or 2% for most variables). Deaths due to noncardiovascular causes were censored. Four-year event rates as a function of different baseline risk features were generated using the corrected group prognosis method.11 This method provides an alternative form for estimating survival rates from the Cox model. The cumulative incidence curves for cardiovascular death, myocardial infarction, or stroke were constructed using the Kaplan-Meier approach. Statistical significance was considered as a 2-sided probability of less than .05. Statistical analyses were performed using SAS version 9 (SAS Institute, Cary, North Carolina).
Of the 68 236 patients enrolled in the REACH Registry who had baseline data, 45 227 who were enrolled at 3647 centers in 29 countries were eligible for inclusion in the 4-year follow-up study and contributed 4-year outcomes data (20 980 patients enrolled at centers that did not participate in 4-year follow-up; 2029 patients did not return after baseline visit) (Figure 1).
The countries included were Austria (n = 1458), Belgium (n = 316), Brazil (n = 331), Canada (n = 1975), Chile (n = 244), China (n = 679), Taiwan (n = 764), Finland (n = 297), France (n = 3904), Germany (n = 4508), Greece (n = 610), Hong Kong (n = 171), Hungary (n = 926), Israel (n = 314), Japan (n = 5073), Malaysia (n = 417), Mexico (n = 801), the Netherlands (n = 305), Philippines (n = 985), Portugal (n = 209), Romania (n = 2005), Russia (n = 999), Spain (n = 1886), Switzerland (n = 632), Thailand (n = 506), United Arab Emirates (n = 150), Ukraine (n = 596), the United Kingdom (n = 496), and the United States (n = 13 670).
The baseline characteristics of the 45 227 patients and the medication use at 4 years in the 31 195 patients who had data at the 4-year follow-up are shown in Table 1. The patients' mean age was 68.4 years and approximately two-thirds were men. Hypertension (81.3%) and hypercholesterolemia (70.4%) were very common; diabetes was present in 43.6% of patients. Polyvascular disease was present in 15.9% of patients; 48.4% had prior ischemic events, with 28.1% of those having an ischemic event within the previous year. A majority of patients were treated with antiplatelet and lipid-lowering therapies.
During the follow-up period, a total of 5481 patients experienced at least 1 event, including 2315 with cardiovascular death, 1228 with myocardial infarction, 1898 with stroke, and 40 with both a myocardial infarction and stroke reported on the case report form as occurring on the same day. Table 2 lists the multivariable predictors of cardiovascular death, myocardial infarction, or stroke at 4 years. The c statistic for this model was 0.68 (95% confidence interval [CI], 0.67-0.69). Bootstrap validation of the c statistic yielded a value of 0.67, only minimally different from the observed value of 0.68. The risk of the triple ischemic end point over time in this population was essentially constant (Figure 2). The model described in Table 2 was refit using a 3-level factor for region: North America/Western Europe, Japan, and all other regions. Two-way interactions were fit between region and the 2 components of the diagnosis: duration of ischemia (3 levels: ≤1 year, >1 year, no ischemia) and type of disease (3 levels: polyvascular, single disease, risk factors only). Neither of these 2-way interactions was significant (P = .76 for duration of ischemia; P = .63 for type of disease). These results indicate that for the diagnosis variable, there was no evidence that the effect of this variable on cardiovascular death, myocardial infarction, or stroke differed by region.
Figure 3 shows the event rates for patients with risk factors only (9.1%; 95% CI, 8.3%-9.9%), stable atherosclerosis without prior ischemic events(12.2%; 95% CI, 11.4%-12.9%), and those with prior ischemic events (18.3%; 95% CI, 17.4%-19.1%), and the additional risk of diabetes (hazard ratio [HR], 1.44; 95% CI, 1.36-1.53; P < .001) or polyvascular disease (HR, 1.99; 95% CI, 1.78-2.24; P < .001) at baseline. From the lowest-risk subgroup to the highest-risk subgroup, the primary end point event rates ranged from 7.1% to 25%.
Table 3 shows the event rates for patients with risk factors only, stable atherosclerosis without prior ischemic events (single/polyvascular disease), and prior ischemic events (single/polyvascular disease). The total number of patients represents those eligible for the 4-year follow-up. The rates of the primary end point and its components are shown. The majority of deaths were due to cardiovascular causes in this population. Rates of cardiovascular hospitalization were high. The cumulative rate of cardiovascular death, myocardial infarction, stroke, or cardiovascular hospitalization ranged from 16.6% in the risk factor–only group to 47.1% in the patients with a baseline history of prior ischemic events and polyvascular disease.
Figure 4 illustrates the additional risk of having an ischemic event during the year prior to enrollment vs more remotely in those patients with a history of an ischemic event at baseline. Those with a prior ischemic event in the past year had a significantly higher rate of cardiovascular death, myocardial infarction, or stroke than those with no ischemic event (HR, 1.71; 95% CI, 1.57-1.85; P < .001).
This analysis of a large international registry demonstrates that there are simple clinical predictors of future ischemic events in patients at various stages along the atherosclerotic continuum. Over the course of 4 years, easily demarcated subgroups of atherothrombotic patients had widely varying risks, ranging from 7% in nondiabetic patients with other risk factors for atherothrombosis to 25% in patients with polyvascular disease and prior ischemic events. This greater than 3-fold gradient in cumulative risk for cardiovascular death, myocardial infarction, or stroke illustrates that not all atherothrombosis is equal—an observation that the broad array of clinicians caring for these types of patients may find clinically relevant.
Patients with prior ischemic events at baseline were at higher risk than patients with stable atherosclerosis but without a history of ischemic events, who in turn were at higher risk than those patients with multiple risk factors only (with no evidence of established atherothrombosis). Among patients with a history of ischemic events, the occurrence of an ischemic event in the year before enrollment was a stronger predictor of future ischemic events than an ischemic event more than a year before enrollment in the registry. Notably, the effects of these factors on event rates within this registry were consistent for all geographic regions included without significant variation, and therefore these findings may be broadly applicable.
Among all categories of patients, diabetes substantially increased the risk of future ischemic events. In those with established atherothrombosis, polyvascular disease was a particularly strong independent risk factor, even stronger than diabetes. These 2 factors were associated with significantly increased risk of the composite end point of cardiovascular death, myocardial infarction, or stroke as well as the individual components of this composite; in addition, they were associated with a significant increase in the risk of cardiovascular hospitalization. When included in the composite end point, cardiovascular hospitalization was associated with nearly doubling of the event rate in all subpopulations analyzed and tracked well with the more objective triple ischemic end point.
These findings should provide clinicians with improved estimates of their patients' future cardiovascular risk and thus enable more effective identification of patients who should be targeted for more intensive follow-up and therapy. Because the majority of patients in this registry would be candidates for basic secondary prevention, such as with statin therapy, future novel therapies may be optimally directed at those with higher levels of risk.12
Thus, even in secondary prevention, simple risk stratification may be incrementally useful, especially as a host of new anti-atherosclerotic and antithrombotic therapies are being developed. New antiplatelet, anticoagulant, anti-atherosclerotic, and anti-inflammatory agents will probably be expensive and may have additional adverse effects; thus, the ability to target these therapies to patients at highest ischemic risk will be desirable and likely would be cost-effective. Although other risk prediction tools have been developed that are effective in the setting of acute coronary syndromes, acute heart failure, or primary prevention, the ability to further risk-stratify patients for advanced secondary prevention will likely be of increasing importance in the future.13-15
These findings also have potential implications for sample size determination for future clinical trials of therapies for atherothrombosis by helping identify those patients at highest risk who are most likely to benefit. For example, the discrepancy between diabetes trials targeting cardiovascular events and the low event rates in those trials illustrates the potential utility of the simple risk enrichment strategies found in the current analysis.6 Planned trials of diabetic patients specifically designed to assess cardiovascular safety may find such simple enrichment strategies particularly useful to avoid low event rates that then create clinical uncertainty over whether diabetic agents provide cardiovascular benefit or harm.16
The presence of established atherothrombosis was found to be a more potent predictor of risk than diabetes in patients with multiple risk factors, so it is not entirely the case that diabetes is an atherosclerosis risk equivalent, as older studies had suggested.17,18 Among patients with atherosclerosis, a history of ischemic events is a stronger predictor than diabetes or stable atherosclerosis, or the combination. Thus, in this analysis, the strongest predictor of future ischemic risk is a history of ischemic events, particularly in the prior year. The concomitant presence of diabetes or polyvascular disease in those patients further identifies an extremely high-risk population.7,9,19,20 The risk model in this analysis has a modest c statistic of 0.68, although this is not dissimilar from some other published cardiovascular risk scores that are in use.13 Regardless, the main purpose of this analysis was to identify simple clinical descriptors of risk that clinicians could easily apply. Risk scores, despite being endorsed by professional society guidelines, are often not used in real-world practice, perhaps due to their perceived complexity with multiple variables.21
The high rate of hospitalization for cardiovascular causes during follow-up is notable, especially due to the attendant economic costs generated.22 Although high hospitalization rates have been recognized as a major problem for medical conditions such as heart failure, the present analysis highlights that patients with a history of, or with several risk factors for, atherothrombosis also have a high hospitalization rate. Even though the majority of patients attending their 4-year visit were treated with antithrombotic therapy and lipid-lowering therapy, the overall rates were not improved compared with the rates at baseline.7 This persistent treatment gap may have contributed in part to their high hospitalization rates and may represent an opportunity to improve care.
Limitations to this analysis are those inherent to registries.23 The follow-up of the initial cohort enrolled was incomplete because some centers and sites were unable to continue in the registry for financial reasons. Nevertheless, there was no evidence that the sites that dropped out were preferentially those with higher or lower ischemic risk, and therefore, there is no reason to think that the overall findings regarding event rates would have been significantly influenced. In fact, the primary end point event rate at 1 year was not significantly different in those with only 1-year follow-up vs those with 1-year and 4-year follow-up. An additional limitation is that end points were not adjudicated, although that is not unusual in a registry.
In conclusion, this analysis of a contemporary, international cohort of patients at various stages of atherothrombosis shows that there is a whole spectrum of ischemic risk in patients with risk factors or with established cardiovascular disease and that easily ascertainable clinical characteristics are the prominent factors associated with a high risk of future ischemic events. Polyvascular disease is the strongest predictor of future ischemic events; a history of previous ischemic events, particularly if such events occurred in the prior 12 months, and a diagnosis of diabetes each are strongly associated with further risk elevation. These findings may help in the identification of high-risk populations who may deserve intensive preventive efforts with novel therapies and also in the planning of future clinical trials.
Corresponding Author: Deepak L. Bhatt, MD, MPH, VA Boston Healthcare System, 1400 VFW Parkway, Boston, MA 02132 (firstname.lastname@example.org).
Published Online: August 30, 2010. doi:10.1001 /jama.2010.1322
Author Contributions: Dr Bhatt had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Bhatt, Ohman, Hirsch, Wilson, Liau, Röther, Steg.
Acquisition of data: Bhatt, Goto, Wilson, Liau, Röther, Steg.
Analysis and interpretation of data: Bhatt, Eagle, Hirsch, Mahoney, Alberts, D’Agostino, Liau, Mas, Röther, Smith Jr, Salette, Contant, Massaro, Steg.
Drafting of the manuscript: Bhatt.
Critical revision of the manuscript for important intellectual content: Bhatt, Eagle, Ohman, Hirsch, Goto, Mahoney, Wilson, Alberts, D’Agostino, Liau, Mas, Röther, Smith Jr, Salette, Contant, Massaro, Steg.
Statistical analysis: D’Agostino, Salette, Contant, Massaro.
Obtained funding: Goto, Röther, Steg.
Administrative, technical, or material support: Bhatt, Ohman, Wilson.
Study supervision: Hirsch, Mas, Röther, Contant, Steg.
Financial Disclosures: Dr Bhatt reported having received institutional research support from AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi-Aventis, and The Medicines Company. Dr Eagle reported having received grant/research support from Bristol-Myers Squibb, Blue Cross Blue Shield of Michigan, the National Institutes of Health (NIH), Sanofi-Aventis, the Mardigian Foundation Varbedian Fund, GORE, and the Hewlett Foundation and being a consultant for the NIH National Heart, Lung, and Blood Institute, Sanofi-Aventis, and the Robert Wood Johnson Foundation. Dr Ohman reported receiving research grants from Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo, Datascope, Eli Lilly, Marquet, Sanofi-Aventis, Schering-Plough, and The Medicines Company and providing consulting or other services for Abiomed, AstraZeneca, CV Therapeutics, Datascope, Gilead Sciences, Liposcience, Marquet, Northpoint Domain, Pozen, Response Biomedical, Sanofi-Aventis, The Medicines Company, and WebMD (theheart.org). Dr Hirsch reported having received research grants from Bristol-Myers Squibb, Sanofi-Aventis, and Abbott Vascular and served as a consultant to Roche, Cytokinetics, ev3, and Talecris. Dr Goto reported having received research grants from Pfizer, Sanofi-Aventis, Ono, Eisai, Otsuka, Sankyo, Daiichi, Takeda, Asteras, Kowa, and AstraZeneca and honoraria from Sanofi-Aventis, Eisai, Otsuka, Daiichi-Sankyo, and Schering-Plough. Dr Mahoney reported having received grant support from Sanofi-Aventis, Bristol-Myers Squibb, Daiichi-Sankyo, and Eli Lilly and honoraria from Sanofi-Aventis and Bristol-Myers Squibb. Dr Wilson reported having received research grants from Sanofi-Aventis. Dr Alberts reported having received research support from AGA Medical, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, EKR, Sanofi-Aventis, and Schering-Plough; having participated in speakers' bureaus for Bristol-Myers Squibb, Boehringer Ingelheim, DiaDexus, Genentech, MedScape, and Sanofi-Aventis; having received honoraria from Bristol-Myers Squibb, Boehringer Ingelheim, DiaDexus, Genentech, MedScape, and Sanofi-Aventis; and having acted as a consultant or advisory board member for Bristol-Myers Squibb, Boehringer Ingelheim, EKR, Genentech, Merck, Pfizer, and Sanofi-Aventis. Dr D’Agostino reported having received honoraria from Sanofi-Aventis. Dr Liau reported no disclosures. Dr Mas reported having received research grants, honoraria, and consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, and Servier and honoraria and consulting fees from Boehringer Ingelheim. Dr Röther reported having participated in speakers' bureaus for Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, and Lundbeck and having acted as a consultant or advisory board member for Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, and Lundbeck. Dr Smith Jr reported no disclosures. Dr Salette reported being an employee of Sanofi-Aventis. Dr Contant reported no disclosures. Dr Massaro reported having received honoraria from Sanofi-Aventis. Dr Steg reported having received research grants (to his institution) from Servier; participating in consultancy or advisory boards for Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Medtronic, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, and The Medicines Company; and being a stockholder in Aterovax.
Funding/Support: The REACH Registry is sponsored by Sanofi-Aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan). The REACH Registry is endorsed by the World Heart Federation.
Role of the Sponsors: The design and conduct of the study were done by the academic executive committee in collaboration with the sponsors; the collection and management of the data were done by the sponsors under the direction of the academic executive committee; analysis was done by the sponsors and independently verified by an academic statistician (Dr Massaro) and those are the analyses presented in the article; the interpretation of the data was done solely by the authors; and the preparation of the first draft of the manuscript was done by Dr Bhatt. All authors reviewed and commented on the manuscript, and all authors gave approval of the submitted manuscript. The sponsors had the opportunity to review but not to approve.
Independent Statistical Analysis: Dr Massaro was provided SAS data sets, the manuscript containing the statistical analytical plan and results, and a blank copy of the study annotated case report forms. Dr Massaro reviewed and regenerated the results of the statistical analysis on the end points in the tables and figures and independently verified the results and conclusions presented in the final manuscript. Those are the analyses and results presented in this article. Dr Massaro was not compensated for the independent statistical review.
REACH Registry Executive Committee: Deepak L. Bhatt, MD, MPH, VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts (chair); Ph. Gabriel Steg, MD, Hôpital Bichat-Claude Bernard, Paris, France (chair); E. Magnus Ohman, MD, Duke University Medical Center, Durham, North Carolina; Joachim Röther, MD, Department of Neurology, Asklepios Klinik Altona, Hamburg, Germany; Peter W. F. Wilson, MD, Emory University School of Medicine, Atlanta, Georgia.
REACH Registry Global Publication Committee: Mark J. Alberts, MD, Northwestern University Medical School, Chicago, Illinois; Deepak L. Bhatt, MD, MPH, VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts (chair); Ralph D’Agostino, PhD, Boston University, Boston; Kim A. Eagle, MD, University of Michigan, Ann Arbor; Shinya Goto, MD, PhD, Tokai University School of Medicine, Isehara, Japan; Alan T. Hirsch, MD, University of Minnesota School of Public Health, Minneapolis; Chiau-Suong Liau, MD, PhD, Taiwan University Hospital and College of Medicine, Taipei, Taiwan; Jean-Louis Mas, MD, Centre Raymond Garcin, Paris, France; E. Magnus Ohman, MD, Duke University Medical Center, Durham, North Carolina; Joachim Röther, MD, Department of Neurology, Asklepios Klinik Altona, Hamburg, Germany; Sidney C. Smith Jr, MD, University of North Carolina at Chapel Hill; Ph. Gabriel Steg, MD, Hôpital Bichat-Claude Bernard, Paris (chair); Peter W. F. Wilson, MD, Emory University School of Medicine, Atlanta, Georgia.
Additional Contributions: The REACH Registry enforces a no ghost-writing policy. The manuscript was written and edited by the authors, who take full responsibility for its content. The first draft was written by Dr Bhatt. Sophie Rushton-Smith, PhD, and Rachel Spice, PhD, assisted with coordinating revisions and provided editorial help in preparing this manuscript, including editing, checking content and language, formatting, referencing, and preparing tables and figures; they received compensation from Sanofi-Aventis. Lucie Parent, an employee of Sanofi-Aventis, provided support for statistical analyses. Milan Novakovic, MD, Sanofi-Aventis, and Nihar Bhakta, MD, Bristol-Myers Squibb, provided support for the REACH Registry. Fang Ren, MS, Brigham and Women's Hospital and the TIMI Study Group, helped with statistical analyses.
A complete list of the REACH Registry Investigators was published in JAMA. 2006;295(2):180-189.
Create a personal account or sign in to: